The chapters of this book report cutting-edge research on molecular events inadiposity and type 2 diabetes, thus opening the way for innovative drug-basedtherapeutic strategies. It addresses all those who wish to keep in touch withrecent developments in the field. Features excellent reviews of international experts on cutting edge diabetes research . Provides a detailed up to date overview of cellular and molecular mechanisms involved in obesity driven development of type 2 diabetes .Focuses on potential novel drug targets, thus opening the way for innovative strategies in diabetes and obesity therapy . INDICE: Preface. Targeting type 2 diabetes. Dual acting and pan-PPAR activators as potential anti-diabetic therapies. GLP-agonists and Dipeptidyl-Peptidase IV Inhibitors. C annabinoids and endocannabinoids in metabolic disorders with focus on diabetes. SGLT Inhibitors as New Therapeutic Tools in the Treatment of Diabetes. Inhibitors of 11 b -hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Nampt and its potential role in inflammation and type 2 diabetes . Inhibition of ganglioside biosynthesis as a novel therapeutic approachin insulin resistance. Overcoming Insulin Resistance with Ciliary Neurotrophic Factor.á Thermogenesis and related metabolic targets in anti-diabetic therapy. Interleukin targeted therapy for metabolic syndrome and type 2 diabetes. Fructose-1, 6-Bisphosphatase Inhibitors for Reducing Excessive Endogenous Glucose Production in Type 2 Diabetes. AMP-activated protein kinase and metabolic control. Mitochondria as potential targets in antidiabetic therapy . Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects .
- ISBN: 978-3-642-17213-7
- Editorial: Springer Berlin Heidelberg
- Encuadernacion: Cartoné
- Páginas: 400
- Fecha Publicación: 01/04/2011
- Nº Volúmenes: 1
- Idioma: Inglés